RGL-305+ Lymphoma + Exploratory Clinical Study

Launched by FUDAN UNIVERSITY · May 28, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the use of a new treatment called RGL-305 for patients with lymphoma who have shown some response to previous standard treatments. Specifically, it is for patients who have either fully responded (complete response) or partially responded (partial response) to treatment but still have some residual cancer cells (known as minimal residual disease or MRD). Participants in the study will receive a special therapy that reinfuses their own modified immune cells to help fight the lymphoma. The trial aims to understand how safe the treatment is and how well it works.

To join the trial, patients need to be between 18 and 75 years old and have a confirmed diagnosis of lymphoma. They must also have had at least one previous treatment and meet certain health criteria. Additionally, participants will need to provide blood or tissue samples for testing. If you or a loved one are considering this trial, be aware that it involves regular check-ups and monitoring to ensure safety and effectiveness. The study is currently recruiting participants, so there may be an opportunity to be part of this important research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntarily participate in the study and sign a written informed consent
• • 2. Age 18-75 years old (including the boundary value), gender is not limited;
• • 3. Patients with pathologically confirmed lymphoma who have previously received at least one standard treatment. After the last treatment, patients with Lugano 2014 lymphoma efficacy evaluation criteria were CR or PR, and MRD was positive. Patients with PR were required to have a Deauville score of 4.
• • 4. Be willing to provide blood or tissue samples required for cytodynamic and biomarker detection before and after treatment;
• • 5. ECOG score is 0 or 1;
• • 6. Expected survival ≥3 months;
• 7. The function of vital organs meets the following criteria:
• • 1. Neutrophil absolute value (ANC) ≥1.0×109/L;
• • 2. Platelet count (PLT) ≥80×109/L;
• • 3. Hemoglobin (Hb) ≥90g/L;
• • 4. International standardized ratio (INR\<1.5), activated partial thromboplastin time (APTT) ≤1.5×ULN;
• • 5. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN);
• • 6. Total bilirubin (TBIL) ≤1.5×ULN;
• • 7. Serum creatinine (Scr) ≤1.5×ULN;
• • 8. Left ventricular ejection fraction (LVEF) ≥45%;
• • 9. Electrocardiogram: Fridericia corrected QT interval (QTcF) \<470 ms; The QTc interval must be corrected according to Fridericia's standard with the correction formula QTcF=QT/RR\^0.33.
• • 8. Fertile female subjects must agree to effective contraception and refrain from egg donation for 6 months from the signing of the informed consent until the last administration of the investigational drug, the serum pregnancy test must be negative within 7 days prior to the first administration, and they are not lactating; Male subjects whose partner is a fertile woman must agree to highly effective contraception and refrain from sperm donation from signing the informed consent until 6 months after the final administration of the investigational drug (see Annex 6 for details)
• Exclusion Criteria:
• • 1. Previous adoptive cell therapy, including but not limited to tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), and T cell receptor chimeric T cells (TCR-T);
• • 2. Have previously received or planned to undergo organ transplantation or allogeneic stem cell or allogeneic bone marrow transplantation;
• • 3. Combined with congenital or acquired immunodeficiency such as cellular immunodeficiency (e.g., DiGeorge syndrome, T-negative severe combined immunodeficiency \[SSCID\]) or combined T-cell and B-cell immunodeficiency (e.g., T-and B-negative combined immunodeficiency, Wiskott-Aldrich syndrome, ataxic telangiectasia, often) See variable immune deficiency); Or infected with human immunodeficiency virus (HIV);
• • 4. The presence of autoimmune diseases, except for patients with hypothyroidism due to autoimmune thyroiditis who only need hormone replacement therapy;
• • 5. History of epilepsy or other central nervous system diseases, or lymphoma invading the central nervous system;
• • 6. Complicated with other malignant tumors, except malignant tumors with disease-free survival of more than 3 years and carcinoma in situ;
• • 7. History of allergy to blood products, known to be allergic to test substances;
• • 8. Any non-hematological toxicity associated with previous treatment does not return to ≤ grade 1, except for hair loss and peripheral neurotoxicity;
• • 9. Those who had undergone major surgery (≥ Grade 3 surgery) within 4 weeks before the start of study treatment, or who required elective surgery during the trial period;
• • 10. Have an poorly controlled or severe cardiovascular disease, such as symptomatic congestive heart failure (NYHA class III or IV), a myocardial infarction within 6 months prior to study initiation, or unstable angina within 1 month prior to study initiation, or an arrhythmia requiring treatment or intervention, Or hypertension remains poorly controlled after adequate treatment (systolic blood pressure ≥150mmHg, diastolic blood pressure ≥90mmHg);
• • 11. Known hereditary or acquired bleeding or thrombotic tendencies;
• • 12. Subjects with a known or highly suspected history of interstitial pneumonia, or evidence of active interstitial pneumonia on chest CT during the pre-screening period; Known history of idiopathic pulmonary fibrosis, institutional pneumonia (such as bronchiolitis obliterans or cryptogenic institutional pneumonia); Subjects who may interfere with the detection or management of suspected drug-related pulmonary toxicity;
• • 13. A severe infection occurring within 28 days prior to study initiation (such as intravenous antibiotics, antifungal, or antiviral drugs as required by clinical practice), or an active infection receiving therapeutic intravenous or oral antibiotics within 14 days prior to study initiation, or an unexplained fever;
• • 14. Active hepatitis B (HBV), hepatitis C (HCV), cytomegalovirus (CMV), EB virus (EBV), HIV, syphilis infection;
• • 15. Plan to receive live attenuated vaccine (inactivated vaccine is allowed) within 28 days before the start of study treatment or during the study period and 90 days after the end of study drug treatment;
• • 16. In the investigator's judgment, the subject has other factors that may affect the study results or lead to the forced termination of the study treatment;
• • 17. During the study period, subjects considering fertility, female subjects became pregnant or breastfed within 6 months of the last study drug administration.